KESPION announces 50% capital reduction and charter amendment to expand new share issuance limit, raising dilution concerns

Extraordinary general meeting of shareholders convened on June 16, 2026: Key agenda includes charter amendment (expansion of business purpose, raising issuance limits for new shares, CB, BW) and approval of a 50% capital reduction.
Capital reduction: 2 common shares will be merged into 1 (50% reduction, 9,588,879 shares canceled), record date July 1, 2026, and changed listing expected on July 23. Purpose is to improve financial structure by covering deficits; opening price on listing date will be adjusted to double the pre-reduction price.
Charter amendment: New share allotment limit expanded from '50% of outstanding shares' to 'total shares to be issued'. Addition of new business acquisition/investment as purpose for third-party allotment, CB, and BW issuance. This increases the potential for dilution of existing shareholders in future large-scale fundraisings.
Business diversification: Entering healthcare (hydrocolloid patches) and zinc-air battery businesses, leveraging growth prospects to diversify revenue.
[AI Comprehensive Analysis]While the capital reduction can improve financial structure, the charter amendment expanding new share issuance limits poses a potential dilution risk to existing shareholders. Given the need for additional funding, negative impact on stock price is anticipated, warranting investor caution.